Loading clinical trials...
Loading clinical trials...
Modulation of Vascular Endothelial Growth Factor (VEGF) Using an Engineered Zinc-Finger Transcription Factor to Treat Lower Limb Intermittent Claudication
Conditions
Interventions
DNA Plasmid Vector
EW-A-401 DNA Plasmid Vector
Locations
3
United States
Baptist Health System, Inc.
Birmingham, Alabama, United States
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
University of Wisconsin
Madison, Wisconsin, United States
Start Date
March 27, 2004
Completion Date
December 29, 2011
Last Updated
December 12, 2019
NCT05132439
NCT07057297
NCT06410521
NCT06670768
NCT05692882
NCT06701968
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions